X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.indianpharmapost.com/drug-approval/gland-pharma-receives-usfda-approval-for-eribulin-mesylate-injection-15492
https://www.prnewswire.com/news-releases/eisai-to-present-preclinical-and-clinical-research-on-eribulin-at-the-2022-san-antonio-breast-cancer-symposium-301690865.html
https://www.prnewswire.com/news-releases/eisai-presents-results-of-post-hoc-analysis-of-eribulin-mesylate-halaven-at-the-european-society-for-medical-oncology-esmo-congress-2022-301621528.html
https://www.acnnewswire.com/press-release/english/69568/eisai-to-present-abstracts-on-oncology-products-and-pipeline-at-esmo-virtual-congress-2021
https://www.prnewswire.com/news-releases/eisai-announces-real-world-data-on-the-effectiveness-of-halaven-eribulin-mesylate-for-the-treatment-of-patients-with-metastatic-breast-cancer-mbc-published-in-advances-in-therapy-301292882.html
https://www.prnewswire.com/news-releases/eisai-to-present-latest-data-from-oncology-pipeline-at-asco-2020-including-keytruda-pembrolizumab-plus-lenvima-lenvatinib-investigational-combination-therapy-and-halaven-eribulin-mesylate-301058986.html
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-halaven-201532-eribulin-mesylate-1-mg2-ml-injection-1581764138.pdf
https://www.biospectrumasia.com/news/25/15261/eisai-launches-anti-cancer-agent-halaven-in-china.html
https://www.biospace.com/article/eisai-s-promotion-and-distribution-agreement-with-mylan-india-for-eribulin-second-brand-in-india/?s=95
https://www.biospectrumasia.com/news/25/14549/eisai-mylan-to-promote-anti-cancer-drug-brands-in-india.html
https://www.thepharmaletter.com/article/eisai-s-halaven-cleared-for-breast-cancer-in-china
https://www.prnewswire.com/news-releases/eisai-announces-additional-data-from-ongoing-phase-1-trial-of-investigational-combination-of-halaven-eribulin-mesylate-with-polyphors-cxcr4-antagonist-balixafortide-in-her2-negative-metastatic-breast-cancer-at-asco-2019-300862113.html
http://www.pharmatimes.com/news/nice_turns_down_earlier_use_of_eisais_halaven_1212682
https://www.europeanpharmaceuticalreview.com/48558/news/industry-news/astrazeneca-phase-iii-breast-cancer/
http://www.fiercepharma.com/pharma/eisai-s-lenvima-moves-toward-nexavar-showdown-phase-3-liver-cancer-win
http://www.reuters.com/article/us-halozyme-study-idUSKBN14P1D5
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/japanese-companies-make-cautious-return-to-indian-pharma-market/articleshow/56320837.cms
http://www.nasdaq.com/article/merck-eisai-announce-interim-data-investigating-keytruda-halaven-combination-20161212-00215
http://www.europeanpharmaceuticalreview.com/45177/news/industry-news/eribulin-breast-cancer/?
http://www.fiercepharma.com/pharma/eisai-wins-nice-backing-for-older-halaven-but-still-isn-t-happy-about-lenvima
http://www.reuters.com/article/us-health-cancer-britain-idUSKBN12Y004
http://www.prnewswire.com/news-releases/eisais-lenvima-lenvatinib-nominated-for-galien-foundations-best-pharmaceutical-product-300351860.html
http://www.prnewswire.com/news-releases/new-halaven-eribulin-and-lenvima-lenvatinib-data-to-be-presented-at-esmo-demonstrate-continued-commitment-to-eisai-oncology-portfolio-300336216.html
http://www.prnewswire.com/news-releases/patienten-in-deutschland-und-osterreich-mit-fortgeschrittenem-liposarkom-haben-jetzt-zugang-zu-halaven-eribulin-der-ersten-substanz-die-als-monotherapie-einen-signifikanten-uberlebensvorteil-zeigen-konnte-578709791.html
http://pharmatimes.com/Article/16-05-05/EU_nod_for_Eisai_s_Halaven_in_liposarcoma.aspx
http://www.prnewswire.com/news-releases/halozyme-therapeutics-and-eisai-to-present-data-evaluating-the-antitumor-effects-of-pegph20-in-combination-with-eribulin-mesylate-in-preclinical-breast-cancer-models-300190249.html
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/swiss-drugmaker-roche-launches-costliest-cancer-drugs-in-india/articleshow/49927222.cms
http://www.fiercepharmaasia.com/story/japans-eisai-present-papers-lenvima-clinical-data-european-cancer-congress/2015-09-14
http://www.fiercepharmaasia.com/story/eisai-sea-sponge-derived-eribulin-shows-sarcoma-treatment-promise/2015-05-31
http://www.pharmatimes.com/Article/15-05-22/Bayer_s_Stivarga_wins_appeal_to_stay_on_CDF.aspx
http://www.fiercepharma.com/story/englands-cancer-drugs-fund-changes-its-tune-holds-novartis-afinitor/2015-03-18
http://www.pmlive.com/pharma_news/cancer_drugs_fund_a_missed_opportunity,_says_mp_677562
http://www.pharmatimes.com/Article/15-03-05/Eisai_and_Merck_in_cancer_combo_deal.aspx
http://www.telegraph.co.uk/news/politics/11340860/25-cancer-drugs-to-be-denied-on-NHS.html
Market Place
Share 
